<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469326</url>
  </required_header>
  <id_info>
    <org_study_id>KC EK-361/05</org_study_id>
    <nct_id>NCT00469326</nct_id>
  </id_info>
  <brief_title>Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study</brief_title>
  <acronym>TIPS</acronym>
  <official_title>Atorvastatin Pre-Treatment Influences the Risk of Percutaneous Coronary Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Motol</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates potential protective effect of atorvastatin pre-treatment in patient
      with stable coronary artery disease undergoing percutaneous coronary intervention (PCI).
      Patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two
      days before PCI) and control group (PCI without atorvastatin pretreatment). Endpoint is
      myocardial infarction measured by troponin I and creatine kinase myocardial band.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized studies have shown that pre-treatment with atorvastatin may reduced periprocedural
      myocardial in patient with stable angina during elective PCI. These data provide
      evidence-based support for using atorvastatin 7 days before PCI (dosage 40mg/d),
      alternatively three or more days (unknown dosage). We want to confirm this results for
      shorter pre-treatment period (two days) with dosage 80mg per day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>periprocedural myocardial infarction measured by troponin I level</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>periprocedural myocardial infarction measured by creatine kinase myocardial band</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin pre-treatment group (80mg atorvastatin two days before PCI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>PCI without atorvastatin pretreatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>two days 80mg atorvastatin pre-treatment before PCI</description>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>Torvacard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable angina in last month

          -  indication for percutaneous coronary intervention

          -  informed consent

        Exclusion Criteria:

          -  acute coronary syndrome in last 14 days

          -  renal insufficiency (creatinine more 150 Âµmol/l)

          -  diseases severely limiting prognosis

          -  immunosuppressive treatment

          -  statin one month before randomization

          -  occlusion of the coronary artery

          -  previous participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Veselka, Prof., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Cardiovascular Center, University Hospital Motol, Prague, Czech Republic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, CardioVascular Center, University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>150 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G; ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004 Aug 10;110(6):674-8. Epub 2004 Jul 26.</citation>
    <PMID>15277322</PMID>
  </reference>
  <reference>
    <citation>Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Bonizzoni E, Ricciardelli B. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004 Oct;25(20):1822-8.</citation>
    <PMID>15474697</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>January 26, 2009</last_update_submitted>
  <last_update_submitted_qc>January 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>University Hospital Motol</name_title>
    <organization>University Hospital Motol</organization>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

